PHAXIAM THERAPEUTICS S.A. PHAXIAM Therapeutics S.A. Euronext Paris
Equities
PHXM
FR0011471135
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.915 EUR | -0.17% |
|
-0.85% | -36.63% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
PHAXIAM Therapeutics S.A. is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, responsible for many serious infections. The company relies on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics S.A. is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
Calendar
2024-05-14
- Q1 2024 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.92
EUR
Average target price
6.85
EUR
Spread / Average Target
+134.59%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -1.55% | 105B | |
| +3.66% | 97.5B | |
| +1.86% | 22.19B | |
| -16.38% | 21.33B | |
| -8.49% | 18.68B | |
| -42.33% | 16.6B | |
| -21.30% | 14.52B | |
| +5.07% | 14.09B | |
| +21.74% | 10.99B |
- Stock Market
- Equities
- PHXM Stock
- PHXM Stock
- News PHAXIAM Therapeutics S.A.
- ERYTECH Pharma S A : Pancreatic Cancer Drug Fails to Meet Primary Endpoint of Late-Stage Study
